Active Ingredient History
Quetiapine, marketed as SEROQUEL XR, is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder. The mechanism of action of SEROQUEL XR in the treatment of schizophrenia, bipolar disorder and major depressive disorder (MDD), is unknown. However, its efficacy in schizophrenia could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2A (5HT2A) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D2, but greater activity at 5HT2A receptors, than the parent drug (quetiapine). Quetiapine’s efficacy in bipolar depression and MDD may partly be explained by the high affinity and potent inhibitory effects that norquetiapine exhibits for the norepinephrine transporter. Antagonism at receptors other than dopamine and serotonin with similar or greater affinities may explain some of the other effects of quetiapine and norquetiapine: antagonism at histamine H1 receptors may explain the somnolence, antagonism at adrenergic α1b receptors may explain the orthostatic hypotension, and antagonism at muscarinic M1 receptors may explain the anticholinergic effects. Quetiapine and norquetiapine have affinity for multiple neurotransmitter receptors including dopamine D1 and D2, serotonin 5HT1A and 5HT2A, histamine H1, muscarinic M1, and adrenergic α1b and α2 receptors. Quetiapine differs from norquetiapine in having no appreciable affinity for muscarinic M1 receptors whereas norquetiapine has high affinity. Quetiapine and norquetiapine lack appreciable affinity for benzodiazepine receptors. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aged (Phase 3)
Alcohol Drinking (Phase 2)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Anorexia Nervosa (Phase 2)
Antipsychotic Agents (Phase 4)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Asthma (Phase 4)
Behavioral Symptoms (Phase 4)
Bipolar Disorder (Phase 4)
Borderline Personality Disorder (Phase 3)
Cocaine-Related Disorders (Phase 4)
Cognition (Phase 3)
Cognitive Dysfunction (Phase 4)
Combat Disorders (Phase 4)
Comorbidity (Phase 4)
COVID-19 (Phase 4)
Delirium (Phase 4)
Dementia (Phase 4)
Dementia, Vascular (Phase 3)
Depression (Phase 4)
Depression, Postpartum (Phase 1)
Depressive Disorder (Phase 3)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drugs, Investigational (Phase 4)
Dyskinesia, Drug-Induced (Phase 1)
Fasting (Phase 1)
Fibromyalgia (Phase 4)
Healthy Volunteers (Phase 4)
Hot Flashes (Phase 4)
Hypercapnia (Phase 1)
Hyperglycemia (Phase 4)
Mania (Phase 4)
Marijuana Abuse (Phase 4)
Marijuana Smoking (Phase 2)
Mental Disorders (Phase 4)
Mental Health (Phase 4)
Metabolic Syndrome (Phase 4)
Methamphetamine (Phase 1)
Mood Disorders (Phase 4)
Morals (Phase 4)
Multiple Sclerosis (Phase 1/Phase 2)
Obsessive Behavior (Phase 4)
Obsessive-Compulsive Disorder (Phase 4)
Panic Disorder (Phase 4)
Parkinson Disease (Phase 4)
Pharmacokinetics (Phase 1)
Phobia, Social (Phase 4)
Pneumonia, Viral (Phase 4)
Postoperative Complications (Phase 3)
Psychomotor Agitation (Phase 4)
Psychophysiologic Disorders (Phase 3)
Quality of Life (Phase 4)
Quetiapine Fumarate (Phase 4)
Respiratory Insufficiency (Phase 1)
Risk Factors (Phase 4)
Schizophrenia (Phase 4)
Sleep (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Substance Abuse, Oral (Phase 4)
Substance-Related Disorders (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
